NCT00705549 - Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions

Non-Small-Cell Lung Cancer

Interventions

DRUG

Gemcitabine

Gemcitabine I.V at the dose of 1000mg/m2 on Day 1 and Day 8

DRUG

Cisplatin

Cisplatin I.V at the dose of 75mg/m2 on Day 1

DRUG

Docetaxel

Docetaxel I.V at the dose of 75mg/m2 on Day 1

DRUG

Cisplatin

Cisplatin I.V at the dose of 80mg/m2 on Day 1

DRUG

Vinorelbine

Vinorelbine per os 50mg every Monday, Wednesday and Friday

DRUG

Pemetrexate

Pemetrexate I.V 500mg/m2 on Day 1

Trial Locations (9)

University General Hospital of Alexandroupolis, Dept. of Medical Oncology, Alexandroupoli

"Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine", Athens

401 Military Hospital, Medical Oncology Unit, Athens

Air Forces Military Hospital, Dep of Medical Oncology, Athens

"IASO General Hospital of Athens, 1st Dep of Medical Oncology", Athens

Sismanogleio General Hospital, 1st, 2nd Dep of Pulmonary Diseases, Athens

"Sotiria General Hospital, 1st, 3rd, 8th Dep of Pulmonary Diseases", Athens

"Metaxa's Anticancer Hospital of Piraeus,1st Dep of Medical Oncology", Piraeus

"Theagenion Anticancer Hospital of Thessaloniki", Thessaloniki